Cargando…

Advanced Alzheimer’s Disease Patients Show Safe, Significant, and Persistent Benefit in 6-Month Bryostatin Trial

BACKGROUND: In pre-clinical studies, Bryostatin, MW (molecular weight) 904, has demonstrated synaptogenic, anti-apoptotic, anti-amyloid, and anti-tau tangle efficacies. OBJECTIVE: To identify AD patients who show significant cognitive benefit versus placebo when treated in a trial with chronic Bryos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alkon, Daniel L., Sun, Miao-Kun, Tuchman, Alan J., Thompson, Richard E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657679/ https://www.ncbi.nlm.nih.gov/pubmed/37742657 http://dx.doi.org/10.3233/JAD-230868

Ejemplares similares

Bryostatin Placebo-Controlled Trials Indicate Cognitive Restoration Above Baseline for Advanced Alzheimer’s Disease in the Absence of Memantine(1)
por: Thompson, Richard E., et al.
Publicado: (2022)

Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer’s Disease Phase IIa and Expanded Access Trials
por: Nelson, Thomas J., et al.
Publicado: (2017)

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease
por: Farlow, Martin R., et al.
Publicado: (2019)

Chronic bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice
por: Cogram, Patricia, et al.
Publicado: (2020)

Bryostatin analog: improving on Nature's design
por: Boger, Dale
Publicado: (2012)

Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.
por: McGown, A. T., et al.
Publicado: (1998)

A phase I study of intravenous bryostatin 1 in patients with advanced cancer.
por: Prendiville, J., et al.
Publicado: (1993)

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
por: Madhusudan, S, et al.
Publicado: (2003)

Munc13 Is a Molecular Target of Bryostatin 1
por: Blanco, Francisco A., et al.
Publicado: (2019)

Bryostatin-1: a promising compound for neurological disorders
por: Tian, Zhen, et al.
Publicado: (2023)

Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply.
por: Thompson, C. H., et al.
Publicado: (1996)

Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors
por: Thijsen, S F T, et al.
Publicado: (1999)

A phase II study of bryostatin 1 in metastatic malignant melanoma.
por: Propper, D. J., et al.
Publicado: (1998)

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
por: Blackhall, F H, et al.
Publicado: (2001)

Neristatin 1 Provides Critical Insight into Bryostatin 1 Structure–Function Relationships
por: Kedei, Noemi, et al.
Publicado: (2015)

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
por: Jayson, G. C., et al.
Publicado: (1995)

Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death
por: Staveness, Daryl, et al.
Publicado: (2016)

Establishment of a murine leukaemia cell line resistant to the growth-inhibitory effect of bryostatin 1.
por: Prendiville, J., et al.
Publicado: (1994)

“Picolog,” a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo
por: DeChristopher, Brian A., et al.
Publicado: (2012)

Designed, Synthetically Accessible Bryostatin Analogues Potently Induce Activation of Latent HIV Reservoirs in vitro
por: DeChristopher, Brian A., et al.
Publicado: (2012)

Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1
por: Martínez-Bonet, Marta, et al.
Publicado: (2015)

Novel pathways of HIV latency reactivation revealed by integrated analysis of transcriptome and target profile of bryostatin
por: Li, Bing-xiang, et al.
Publicado: (2020)

Synthesis of seco-B-Ring Bryostatin Analogue WN-1 via C–C Bond-Forming Hydrogenation: Critical Contribution of the B-Ring in Determining Bryostatin-like and Phorbol 12-Myristate 13-Acetate-like Properties
por: Andrews, Ian P., et al.
Publicado: (2014)

The ε-Isozyme of Protein Kinase C (PKCε) Is Impaired in ALS Motor Cortex and Its Pulse Activation by Bryostatin-1 Produces Long Term Survival in Degenerating SOD1-G93A Motor Neuron-like Cells
por: La Cognata, Valentina, et al.
Publicado: (2023)

Synthesis of a des-B-Ring Bryostatin Analogue Leads to an Unexpected Ring Expansion of the Bryolactone Core
por: Kraft, Matthew B., et al.
Publicado: (2014)

Bryostatin-1 Attenuates Ischemia-Elicited Neutrophil Transmigration and Ameliorates Graft Injury after Kidney Transplantation
por: Becker, Felix, et al.
Publicado: (2022)

PKC modulator bryostatin-1 therapeutically targets CNS innate immunity to attenuate neuroinflammation and promote remyelination
por: Gharibani, Payam, et al.
Publicado: (2023)

Bryostatin‐1 ameliorated experimental colitis in Il‐10 (−/−) Mice by protecting the intestinal barrier and limiting immune dysfunction
por: Zuo, Lugen, et al.
Publicado: (2019)

Alzheimer’s Disease: Significant Benefit from the Yeast-Based Models
por: Epremyan, Khoren K., et al.
Publicado: (2023)

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
por: Clamp, A R, et al.
Publicado: (2003)

Phorbol ester and bryostatin effects on growth and the expression of oestrogen responsive and TGF-beta 1 genes in breast tumour cells.
por: Nutt, J. E., et al.
Publicado: (1991)

Computer-Guided Design, Synthesis, and Protein Kinase C Affinity of a New Salicylate-Based Class of Bryostatin Analogs
por: Wender, Paul A., et al.
Publicado: (2014)

Contrasting effect of the latency-reversing agents bryostatin-1 and JQ1 on astrocyte-mediated neuroinflammation and brain neutrophil invasion
por: Proust, Alizé, et al.
Publicado: (2017)

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
por: López-Huertas, María Rosa, et al.
Publicado: (2017)

Population data science: advancing the safe use of population data for public benefit
por: Jones, Kerina Helen, et al.
Publicado: (2018)

Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Improved Protein Kinase C Affinity through Final Step Diversification of a Simplified Salicylate-Derived Bryostatin Analog Scaffold
por: Wender, Paul A., et al.
Publicado: (2014)

Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism
por: Díaz, Laura, et al.
Publicado: (2015)

Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent Manner
por: Mehla, Rajeev, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_3rnt2e3qbljiesj94r67hdavq6